272 related articles for article (PubMed ID: 15857674)
21. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
22. Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene.
Janson CG; Kolodny EH; Zeng BJ; Raghavan S; Pastores G; Torres P; Assadi M; McPhee S; Goldfarb O; Saslow B; Freese A; Wang DJ; Bilaniuk L; Shera D; Leone P
Ann Neurol; 2006 Feb; 59(2):428-31. PubMed ID: 16437572
[TBL] [Abstract][Full Text] [Related]
23. Immune responses to AAV in a phase I study for Canavan disease.
McPhee SW; Janson CG; Li C; Samulski RJ; Camp AS; Francis J; Shera D; Lioutermann L; Feely M; Freese A; Leone P
J Gene Med; 2006 May; 8(5):577-88. PubMed ID: 16532510
[TBL] [Abstract][Full Text] [Related]
24. Accumulation of N-acetyl-L-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system.
Kitada K; Akimitsu T; Shigematsu Y; Kondo A; Maihara T; Yokoi N; Kuramoto T; Sasa M; Serikawa T
J Neurochem; 2000 Jun; 74(6):2512-9. PubMed ID: 10820213
[TBL] [Abstract][Full Text] [Related]
25. Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease.
Leone P; Janson CG; McPhee SJ; During MJ
Curr Opin Mol Ther; 1999 Aug; 1(4):487-92. PubMed ID: 11713764
[TBL] [Abstract][Full Text] [Related]
26. Current development of adeno-associated viral vectors.
Romano G
Drug News Perspect; 2005 Jun; 18(5):311-6. PubMed ID: 16193103
[TBL] [Abstract][Full Text] [Related]
27. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
Eke GH; Iscan A; Cece H; Calik M
Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
[TBL] [Abstract][Full Text] [Related]
28. Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo.
McCown TJ
Mol Ther; 2006 Jul; 14(1):63-8. PubMed ID: 16730475
[TBL] [Abstract][Full Text] [Related]
29. Canavan disease: a monogenic trait with complex genomic interaction.
Surendran S; Michals-Matalon K; Quast MJ; Tyring SK; Wei J; Ezell EL; Matalon R
Mol Genet Metab; 2003; 80(1-2):74-80. PubMed ID: 14567959
[TBL] [Abstract][Full Text] [Related]
30. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
[TBL] [Abstract][Full Text] [Related]
31. Aspartoacylase gene knockout results in severe vacuolation in the white matter and gray matter of the spinal cord in the mouse.
Surendran S; Campbell GA; Tyring SK; Matalon R
Neurobiol Dis; 2005 Mar; 18(2):385-9. PubMed ID: 15686967
[TBL] [Abstract][Full Text] [Related]
32. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors.
Raake PW; Hinkel R; Müller S; Delker S; Kreuzpointner R; Kupatt C; Katus HA; Kleinschmidt JA; Boekstegers P; Müller OJ
Gene Ther; 2008 Jan; 15(1):12-7. PubMed ID: 17943147
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of aspartoacylase activity in the duodenum of obesity induced diabetes mouse: implications on diabetic neuropathy.
Surendran S; Matalon R; Tyring SK
Biochem Biophys Res Commun; 2006 Jul; 345(3):973-5. PubMed ID: 16707098
[TBL] [Abstract][Full Text] [Related]
34. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model.
Becker I; Wang-Eckhardt L; Eckhardt M
J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891
[TBL] [Abstract][Full Text] [Related]
35. IGF-1 gene therapy to protect articular cartilage in a rat model of joint damage.
Izal I; Acosta CA; Ripalda P; Zaratiegui M; Ruiz J; Forriol F
Arch Orthop Trauma Surg; 2008 Feb; 128(2):239-47. PubMed ID: 17661064
[TBL] [Abstract][Full Text] [Related]
36. Rapid detection of three large novel deletions of the aspartoacylase gene in non-Jewish patients with Canavan disease.
Zeng BJ; Wang ZH; Torres PA; Pastores GM; Leone P; Raghavan SS; Kolodny EH
Mol Genet Metab; 2006; 89(1-2):156-63. PubMed ID: 16854607
[TBL] [Abstract][Full Text] [Related]
37. A novel aspartoacylase (ASPA) gene mutation in Canavan disease.
Durmaz AA; Akin H; Onay H; Vahabi A; Ozkinay F
Fetal Pediatr Pathol; 2012 Aug; 31(4):236-9. PubMed ID: 22468686
[TBL] [Abstract][Full Text] [Related]
38. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.
Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B
Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223
[TBL] [Abstract][Full Text] [Related]
39. Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model.
Yang X; Mertens B; Lehtonen E; Vercammen L; Bockstael O; Chtarto A; Levivier M; Brotchi J; Michotte Y; Baekelandt V; Sarre S; Tenenbaum L
J Gene Med; 2009 Oct; 11(10):899-912. PubMed ID: 19639608
[TBL] [Abstract][Full Text] [Related]
40. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
